Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 5:07 AM
Ignite Modification Date:
2025-12-25 @ 5:07 AM
NCT ID:
NCT01472627
Eligibility Criteria:
Inclusion Criteria:
* Newly diagnosed multiple myeloma
* Therapy with bortezomib alone or bortezomib/dexamethasone being initiated as the standard of care therapy for myeloma by their treating physician
Exclusion Criteria:
* Hypersensitivity to bortezomib, boron or mannitol
* Treatment with other investigational drugs within 28 days before enrollment
* Diagnosed or treated for another malignancy within 6 months of enrollment, with the exception of complete resection of basal cell carcinoma or squamous cell carcinoma of the skin, an in situ malignancy, or low-risk prostate cancer after curative therapy
* Use of other myeloma directed therapy (except for dexamethasone) in combination with bortezomib
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT01472627
Study Brief:
Protocol Section:
NCT01472627